Clinical pharmacology and therapy · 2021 · 10 citations · 13 references
MedicineObstetricsPharmacotherapyClinical PharmacologyObstetric HemorrhageEmergency Obstetric CareObstetric Hemorrhage ManagementAtypical Hemolytic Uremic Syndrome TherapyComparative Efficacy EvidenceEculizumab Therapy
Obstetric atypical hemolytic-uremic syndrome (aHUS) is an emergency with an unfavorable prognosis. The implementation of the complement-blocking drug Eculizumab into clinical practice significantly improved prognosis of patients with obstetric aHUS. In 2019, the first biosimilar of Eculizumab was developed in Russia by GENERIUM.
13
Marina Noris, Jessica Caprioli, Elena Bresin et al. · Clinical Journal of the American Society of Nephrology · 2010 · 1K citations · Full text
Fádi Fakhouri, Maryvonne Hourmant, Josep M. Campistol et al. · American Journal of Kidney Diseases · 2016 · 308 citations · Full text